Prakhar Agrawal Analyst PerformanceSenior Biotechnology Analyst at Cantor FitzgeraldPrakhar Agrawal is a stock analyst at Cantor Fitzgerald focused in the healthcare sector, covering 27 publicly traded companies. Over the past year, Prakhar Agrawal has issued 8 stock ratings, including and buy recommendations. While full access to Prakhar Agrawal's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Prakhar Agrawal's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings62 Last 4 YearsBuy Recommendations86.89% 53 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution61RatingsDistribution of strong buy, buy, hold, and sell ratings by Prakhar Agrawal.RatingPercentageCount Strong Buy14.8%9 ratings Buy72.1%44 ratings Hold13.1%8 ratings Sell0.0%0 ratingsOut of 61 total stock ratings issued by Prakhar Agrawal at Cantor Fitzgerald, the majority (72.1%) have been Buy recommendations, followed by 14.8% Strong Buy and 13.1% Hold.Best & Worst CallsBest Call0000.0%TGTXMay 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NEXIJun 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ85.2% of companies on NASDAQ23 companiesNYSE7.4% of companies on NYSE2 companiesOTCMKTS7.4% of companies on OTCMKTS2 companiesPrakhar Agrawal, an analyst at Cantor Fitzgerald, currently covers 27 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare26 companies96.3%Miscellaneous1 company3.7%Prakhar Agrawal of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY22 companies81.5%PHARMACEUTICALS4 companies14.8%Miscellaneous1 company3.7% Prakhar Agrawal's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsTRXBTRex Bio11/3/2026Initiated Coverage$13.64Overweight$0.0000.00% ROIMANEVeradermics10/19/2026Reiterated Rating$109.16Overweight$0.0000.00% ROIIVAInventiva7/17/2026Initiated Coverage$4.52Overweight$0.0000.00% ROISLNSilence Therapeutics6/24/2026Initiated Coverage$7.27Overweight$0.0000.00% ROISTTKShattuck Labs4/27/2026Initiated Coverage$7.74Overweight$0.0000.00% ROIMANEVeradermics3/2/2026Initiated Coverage$45.70Overweight$0.0000.00% ROIAKROAkero Therapeutics12/10/2025Reiterated Rating$54.65Overweight$0.0000.00% ROIEVMNEvommune12/1/2025Initiated Coverage$20.71Overweight$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/4/2025Upgrade$444.64Overweight$000.0000.00% ROIAVTXAvalo Therapeutics8/15/2025Initiated Coverage$8.95Overweight$00.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. GPCRStructure Therapeutics6/23/2025Reiterated Rating$21.98$65.00Overweight$00.0000.00% ROIORICOric Pharmaceuticals5/6/2025Reiterated Rating$5.70Overweight$0.0000.00% ROITVTXTravere Therapeutics4/23/2025Reiterated Rating$17.30Overweight$00.0000.00% ROITVTXTravere Therapeutics4/3/2025Reiterated Rating$16.01Overweight$00.0000.00% ROIACRSAclaris Therapeutics3/18/2025Initiated Coverage$1.58Overweight$0.0000.00% ROIACRSAclaris Therapeutics3/4/2025Upgrade$1.93Strong-Buy$0.0000.00% ROIARDXArdelyx3/4/2025Upgrade$5.41Strong-Buy$0.0000.00% ROIIMVTImmunovant3/4/2025Upgrade$18.49Strong-Buy$00.0000.00% ROIROIVRoivant Sciences3/4/2025Upgrade$10.32Strong-Buy$00.0000.00% ROITVTXTravere Therapeutics2/21/2025Reiterated Rating$22.18Overweight$00.0000.00% ROIACRSAclaris Therapeutics1/30/2025Upgrade$2.48Strong-Buy$0.0000.00% ROIARDXArdelyx1/30/2025Upgrade$5.36Strong-Buy$0.0000.00% ROIIMVTImmunovant1/30/2025Upgrade$21.74Strong-Buy$00.0000.00% ROIROIVRoivant Sciences1/30/2025Upgrade$11.13Strong-Buy$00.0000.00% ROIKROSKeros Therapeutics1/21/2025Downgrade$10.86Neutral$00.0000.00% ROIZLDPFZealand Pharma A/S1/21/2025Upgrade$102.98Strong-Buy$00.0000.00% ROIORICOric Pharmaceuticals1/14/2025Reiterated Rating$9.45Overweight$00.0000.00% ROITVTXTravere Therapeutics1/10/2025Initiated Coverage$18.54Overweight$00.0000.00% ROIATYRaTyr Pharma1/6/2025Initiated Coverage$3.98Overweight$0.0000.00% ROIKROSKeros Therapeutics11/22/2024Reiterated Rating$53.90Overweight$00.0000.00% ROIMDGLMadrigal Pharmaceuticals11/20/2024Reiterated Rating$314.17Neutral$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital MarketsRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
